4//SEC Filing
Shaaltiel Yoseph 4
Accession 0001209191-10-012578
CIK 0001006281other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 4:18 PM ET
Size
6.4 KB
Accession
0001209191-10-012578
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Award
Stock Options (Right to Buy)
2010-02-25+145,000→ 145,000 totalExercise: $6.90Exp: 2020-02-25→ Common Stock (145,000 underlying)
Footnotes (2)
- [F1]The options vest quarterly, in 12 equal tranches over a three-year period, commencing upon the U.S. Food and Drug Administration's marketing approval of taliglucerase alfa, if at all, and are subject to accelerated vesting upon a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan.
- [F2]Does not include options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019 and options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001385118
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 4:18 PM ET
- Size
- 6.4 KB